Biovista

ChemDiv, a fully Integrated Target-to-Market Contract Research Organization (CRO) headquartered in San Diego, CA USA.
ChemDiv provides integrated drug discovery and early clinical development deliverables by extracting added value from potential therapeutic candidates via rapid, streamlined outcomes and effective use of capital.

- 25 years experience and 2500 customers worldwide
- Premium R&D CRO based in USA with global reach
- Seasoned project managers
- Extensive Academic partnerships
- Flexible business models
- Competitive pricing options
- Industry's largest ever-greening stock compound inventory
- Ongoing investments in novel proprietary chemistry and discovery platforms

One of the oldest CROs in the industry, ChemDiv provides Integrated Discovery outSource™ solutions that cover the complete range of disciplines needed to bring new drugs for treatment of CNS, oncology, inflammation, metabolic and infectious diseases from target to candidate and through clinical Proof of Concept to the market. ChemDiv champions collaborative development models with co-investors to rescue under-exploited R&D assets for pharmaceutical and biotech partners.

Envigo provides the broadest range of research models and related services to the pharmaceutical and biotechnology industries, government, academia, and other life science organizations. As the largest organization that is solely dedicated to providing research models and related products and services, we are committed to helping researchers realize the full potential of their critical R&D projects as we fulfill our mission to work together to build a healthier and safer world. Read more at envigo.com

The ESTERN Medical CRO Corporation Group is one of the world's leading Life Sciences, full International Clinical Contract Research Organization, conducting clinical trials in the US-North America & Latin America (LATAM). We operate in two continents, in US-North America and Latin America. Our corporate offices are located in Boston / Cambridge, Massachusetts, USA and our regional offices across Mexico, Brazil, Colombia, Chile & Argentina. As privately owned corporation, since its foundation in 2002 we are passionate about being the preferred full service CRO partner worldwide, thus contributing to people’s health and quality of life.

This leadership is built on our internal skills and competencies, and is complemented by collaboration with external partners and clients that include Global Pharmaceutical, Biotechnology, Medical Device, MedTechs, CROs, & Academic - Government Institutions. ESTERN applies innovative dynamic Clinical, Operational & Regulatory Development and a broad track record of therapeutic expertise to our clients. We emphasize our commitment to quality to help our sponsors and partners maximize returns on their R&D investments and accelerate the delivery of safe & effective therapeutics to patients globally.

ESTERN provides outsourced clinical trial services across all phases, through its years of experience, ESTERN has developed the operational and therapeutic expertise to provide high quality, international service while maintaining our differentiating personal interaction element of commitment to excellence.

Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The Company’s multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. Evotec leverages this “Data-driven R&D Autobahn to Cures” for proprietary projects and within a network of partners including all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 200 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec operates globally with more than 3,700 highly qualified people. The Company’s 14 sites offer highly synergistic technologies and services and operate as complementary clusters of excellence.

Ora is the world's leading full-service ophthalmic drug and device development firm with offices in the United States, United Kingdom, Australia, and Asia. For over 40 years, we have proudly helped our clients earn more than 45 product approvals. We support a wide array of organizations, from start-ups to global pharmaceutical and device companies, to efficiently bring their new products from concept to market. Ora's pre-clinical and clinical models, unique methodologies, and global regulatory strategies have been refined and proven across thousands of global projects. We bring together the world's most extensive and experienced team of ophthalmic experts, R&D professionals, and management executives to maximize the value of new product initiatives.